New cholesterol drug candidate enters early human testing

NCT ID NCT07152873

Not yet recruiting Disease control Sponsor: Addpharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. The main goal is to check safety and drug levels in the blood, not yet to see if it treats the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-117 (a drug for mixed dyslipidemia)
What this could lead to: If successful, this could lead to a new treatment option for managing mixed dyslipidemia, a condition with high cholesterol and triglycerides.
What could go wrong: This is an early Phase 1 trial in healthy volunteers, not patients. It only tests safety and drug processing, not whether the drug actually works for the condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia, familial combined, LPL related

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIXED DYSLIPIDEMIA

Contacts and locations

Locations

H Plus Yangji Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.